Quantum Computing in Drug Discovery Market - 2026-2035
Quantum Computing in Drug Discovery Market reached US$ 126.11 million in 2025 and is expected to reach US$ 637.83 million by 2035, growing with a CAGR of 17.90% during the forecast period 2026-2035.
The Quantum Computing in Drug Discovery Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Quantum Computing in Drug Discovery Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Offering
Both primary and secondary data sources have been used in the global Quantum Computing in Drug Discovery Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
The Quantum Computing in Drug Discovery Market emerges as a key focus in DataM Intelligence latest in-depth analysis, where seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.
A Quantum Computing in Drug Discovery Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.
By Offering
- Hardware*
- Software
- Services
- Superconducting Qubits*
- Trapped-Ion Qubits
- Photonic Qubits
- Quantum Annealing
- Topological Qubits
- Target Identification & Validation*
- Hit Generation/Lead Identification
- Lead Optimization
- Preclinical Candidate Selection
- Quantum Simulation*
- Quantum Optimization
- Quantum Machine Learning
- Quantum Sampling
- Cloud-Based*
- On-Premises
- Oncology*
- Infectious Diseases
- Cardiovascular Disorders
- Neurological Disorders
- Immunological Disorders
- Rare & Orphan Diseases
- Metabolic & Endocrine Disorders
- Others
- Pharmaceutical Companies*
- Biopharmaceutical Companies
- Contract Research Organizations (CROs)
- Academic & Research Institutes
- Others
- North America (U.S., Canada, Mexico)
- Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
- Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
- South America (Colombia, Brazil, Argentina, Rest of South America)
- Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)
- Go-to-market Strategy.
- Neutral perspective on the market performance.
- Development trends, competitive landscape analysis, supply side analysis, demand side analysis, year-on-year growth, competitive benchmarking, vendor identification, and other significant analysis, as well as development status.
- Customized regional/country reports as per request and country level analysis.
- Potential & niche segments and regions exhibiting promising growth covered.
- Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape and Major Players (Innovators, Start-ups, Laggard, and Pioneer).
Both primary and secondary data sources have been used in the global Quantum Computing in Drug Discovery Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.
1. METHODOLOGY AND SCOPE
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Demand to Reduce Drug Discovery Time and R&D Costs Drives Market Growth
4.1.1.2. Advanced Molecular Simulation Capabilities Accelerate Adoption of Quantum Computing in Drug Discovery
4.1.1.3. Increasing Pharmaceutical R&D Investments Fuel Quantum Drug Discovery Market Expansion
4.1.2. Restraints
4.1.2.1. Limited Quantum Hardware Scalability and High Error Rates Restrain Market Growth
4.1.2.2. High Implementation Costs and Infrastructure Challenges Limit Adoption
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Expansion of Quantum-as-a-Service (QaaS) Platforms Creates New Growth Avenues
4.1.4.2. Growing Focus on Precision Medicine and Rare Diseases Drives Market Opportunities
4.1.5. Trends
4.1.5.1. Rising Strategic Collaborations Between Quantum Firms and Pharma Companies Accelerate Innovation
4.1.5.2. Increasing Focus on Near-Term Use Cases Such as Molecular Simulation and Lead Optimization
4.1.6. Challenges
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
5.3.1. Increasing Demand for Faster and More Efficient Drug Development
5.3.2. Growing Awareness of Advanced Technologies in Healthcare Innovation
5.3.3. Expansion of Collaborative Research Ecosystems
5.4. Economic Factors
5.4.1. Rising Investments in Quantum Computing and Pharmaceutical R&D
5.4.2. Long-Term Cost Efficiency in Drug Development
5.4.3. Government Funding and Policy Support for Quantum Technologies
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY OFFERING
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
6.1.2. Market Attractiveness Index, By Offering
6.2. Hardware*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Software
6.4. Services
7. BY QUANTUM TECHNOLOGY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Quantum Technology Type
7.1.2. Market Attractiveness Index, By Quantum Technology Type
7.2. Superconducting Qubits*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Trapped-Ion Qubits
7.4. Photonic Qubits
7.5. Quantum Annealing
7.6. Topological Qubits
8. BY DRUG DISCOVERY WORKFLOW STAGE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Discovery Workflow Stage
8.1.2. Market Attractiveness Index, By Drug Discovery Workflow Stage
8.2. Target Identification & Validation*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hit Generation/Lead Identification
8.4. Lead Optimization
8.5. Preclinical Candidate Selection
9. BY COMPUTATIONAL APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Computational Application
9.1.2. Market Attractiveness Index, By Computational Application
9.2. Quantum Simulation*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Quantum Optimization
9.4. Quantum Machine Learning
9.5. Quantum Sampling
10. BY DEPLOYMENT MODEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Model
10.1.2. Market Attractiveness Index, By Deployment Model
10.2. Cloud-Based*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. On-Premises
11. BY THERAPEUTIC AREA
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.1.2. Market Attractiveness Index, By Therapeutic Area
11.2. Oncology*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Infectious Diseases
11.4. Cardiovascular Disorders
11.5. Neurological Disorders
11.6. Immunological Disorders
11.7. Rare & Orphan Diseases
11.8. Metabolic & Endocrine Disorders
11.9. Others
12. BY END-USER
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.1.2. Market Attractiveness Index, By End-User
12.2. Pharmaceutical Companies*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Biopharmaceutical Companies
12.4. Contract Research Organizations (CROs)
12.5. Academic & Research Institutes
12.6. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America*
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Quantum Technology Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Discovery Workflow Stage
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Computational Application
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Model
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.10.1. U.S.
13.2.10.2. Canada
13.2.10.3. Mexico
13.3. Europe
13.3.1. Germany
13.3.2. UK
13.3.3. France
13.3.4. Russia
13.3.5. Spain
13.3.6. Italy
13.3.7. Poland
13.3.8. Rest of Europe
13.4. Latin America
13.4.1. Brazil
13.4.2. Argentina
13.4.3. Rest of Latin America
13.5. Asia-Pacific
13.5.1. China
13.5.2. India
13.5.3. Japan
13.5.4. Australia
13.5.5. South Korea
13.5.6. Indonesia
13.5.7. Malaysia
13.5.8. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. UAE
13.6.2. Saudi Arabia
13.6.3. South Africa
13.6.4. Israel
13.6.5. Turkiye
13.6.6. Rest of Middle East and Africa
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Market Share Analysis - Global
14.3. Market Share Analysis - North America
14.4. Market Share Analysis - Europe
14.5. Market Share Analysis - Asia-Pacific
14.6. Mergers and Acquisitions Analysis
14.7. Partner Identification Analysis
14.8. Investment & Funding Landscape
14.9. Strategic Alliances & Innovation Pipeline
15. COMPANY PROFILES
15.1. IBM*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Revenue Analysis
15.1.4. Pricing Analysis
15.1.5. SWOT Analysis
15.1.6. Recent Developments
15.1.6.1. Major Deals
15.1.6.2. M&A
15.1.6.3. Collaboration
15.1.6.4. Acquisition
15.1.6.5. Joint Ventures
15.1.6.6. Innovations
15.1.7. Recent News
15.1.7.1. Events
15.1.7.2. Conferences
15.1.7.3. Symposiums
15.1.7.4. Webinars
15.2. D-Wave Quantum Inc.
15.3. Microsoft
15.4. Rigetti & Co, LLC.
15.5. Intel Corporation
15.6. Fujitsu
15.7. Xanadu
15.8. Quantum Brilliance Pty Ltd
15.9. Zapata Quantum, Inc.
15.10. QuEra Computing Inc.
15.11. Qubit Pharmaceuticals (LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
1.1. Research Data
1.1.1. Secondary Data
1.1.2. Primary Data
1.1.3. CAGR Analysis
1.2. Market Size Estimation Methodology
1.2.1. Bottom-Up Approach
1.2.2. Top-Down Approach
1.3. Market Breakdown & Data Triangulation
1.4. Research Assumptions
1.5. Limitations
2. DEFINITION AND OVERVIEW
2.1. Study Objectives
2.2. Market Definition
2.3. Market Scope
2.4. Stakeholder Analysis
2.5. Currency Considered
2.6. Study Period
3. EXECUTIVE SUMMARY
3.1. Key Takeaways
3.2. Top To Bottom Analysis
3.3. Market Share Analysis
3.4. Data Points from Key Primary Interviews
3.5. Data Points from Key Secondary Databases
3.6. Market Snapshot
3.7. Geographical Snapshot
4. DYNAMICS
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Rising Demand to Reduce Drug Discovery Time and R&D Costs Drives Market Growth
4.1.1.2. Advanced Molecular Simulation Capabilities Accelerate Adoption of Quantum Computing in Drug Discovery
4.1.1.3. Increasing Pharmaceutical R&D Investments Fuel Quantum Drug Discovery Market Expansion
4.1.2. Restraints
4.1.2.1. Limited Quantum Hardware Scalability and High Error Rates Restrain Market Growth
4.1.2.2. High Implementation Costs and Infrastructure Challenges Limit Adoption
4.1.3. Impact Analysis - Drivers and Restraints
4.1.4. Opportunity
4.1.4.1. Expansion of Quantum-as-a-Service (QaaS) Platforms Creates New Growth Avenues
4.1.4.2. Growing Focus on Precision Medicine and Rare Diseases Drives Market Opportunities
4.1.5. Trends
4.1.5.1. Rising Strategic Collaborations Between Quantum Firms and Pharma Companies Accelerate Innovation
4.1.5.2. Increasing Focus on Near-Term Use Cases Such as Molecular Simulation and Lead Optimization
4.1.6. Challenges
5. INDUSTRY ANALYSIS
5.1. Porter’s Five Force Analysis
5.2. Political Factors
5.3. Social Factors
5.3.1. Increasing Demand for Faster and More Efficient Drug Development
5.3.2. Growing Awareness of Advanced Technologies in Healthcare Innovation
5.3.3. Expansion of Collaborative Research Ecosystems
5.4. Economic Factors
5.4.1. Rising Investments in Quantum Computing and Pharmaceutical R&D
5.4.2. Long-Term Cost Efficiency in Drug Development
5.4.3. Government Funding and Policy Support for Quantum Technologies
5.5. Geopolitical Factors
5.6. Supply/Value Chain Analysis
5.7. Pricing Analysis
5.8. Regulatory Analysis
5.9. Technology Landscape
5.10. Innovation & R&D Trends
5.11. Sustainability and ESG Analysis
5.12. Risk Avoidance Model
5.13. Go-To-Market (GTM) Strategy
5.14. BCG Matrix
5.15. Business Models Analysis
5.16. Demand-Supply Gap
5.17. Risk Mitigation Framework
5.18. Compliance Roadmap
5.19. Strategic Implications
5.20. Emerging Opportunities
5.21. Adoption Trends
5.22. Disruption Analysis
5.23. DMI Opinion
6. BY OFFERING
6.1. Introduction
6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
6.1.2. Market Attractiveness Index, By Offering
6.2. Hardware*
6.2.1. Introduction
6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Software
6.4. Services
7. BY QUANTUM TECHNOLOGY TYPE
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Quantum Technology Type
7.1.2. Market Attractiveness Index, By Quantum Technology Type
7.2. Superconducting Qubits*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Trapped-Ion Qubits
7.4. Photonic Qubits
7.5. Quantum Annealing
7.6. Topological Qubits
8. BY DRUG DISCOVERY WORKFLOW STAGE
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Discovery Workflow Stage
8.1.2. Market Attractiveness Index, By Drug Discovery Workflow Stage
8.2. Target Identification & Validation*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Hit Generation/Lead Identification
8.4. Lead Optimization
8.5. Preclinical Candidate Selection
9. BY COMPUTATIONAL APPLICATION
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Computational Application
9.1.2. Market Attractiveness Index, By Computational Application
9.2. Quantum Simulation*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Quantum Optimization
9.4. Quantum Machine Learning
9.5. Quantum Sampling
10. BY DEPLOYMENT MODEL
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Model
10.1.2. Market Attractiveness Index, By Deployment Model
10.2. Cloud-Based*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. On-Premises
11. BY THERAPEUTIC AREA
11.1. Introduction
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
11.1.2. Market Attractiveness Index, By Therapeutic Area
11.2. Oncology*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Infectious Diseases
11.4. Cardiovascular Disorders
11.5. Neurological Disorders
11.6. Immunological Disorders
11.7. Rare & Orphan Diseases
11.8. Metabolic & Endocrine Disorders
11.9. Others
12. BY END-USER
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
12.1.2. Market Attractiveness Index, By End-User
12.2. Pharmaceutical Companies*
12.2.1. Introduction
12.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
12.3. Biopharmaceutical Companies
12.4. Contract Research Organizations (CROs)
12.5. Academic & Research Institutes
12.6. Others
13. BY REGION
13.1. Introduction
13.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
13.1.2. Market Attractiveness Index, By Region
13.2. North America*
13.2.1. Introduction
13.2.2. Key Region-Specific Dynamics
13.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering
13.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Quantum Technology Type
13.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Discovery Workflow Stage
13.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Computational Application
13.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Model
13.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area
13.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
13.2.10. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
13.2.10.1. U.S.
13.2.10.2. Canada
13.2.10.3. Mexico
13.3. Europe
13.3.1. Germany
13.3.2. UK
13.3.3. France
13.3.4. Russia
13.3.5. Spain
13.3.6. Italy
13.3.7. Poland
13.3.8. Rest of Europe
13.4. Latin America
13.4.1. Brazil
13.4.2. Argentina
13.4.3. Rest of Latin America
13.5. Asia-Pacific
13.5.1. China
13.5.2. India
13.5.3. Japan
13.5.4. Australia
13.5.5. South Korea
13.5.6. Indonesia
13.5.7. Malaysia
13.5.8. Rest of Asia-Pacific
13.6. Middle East and Africa
13.6.1. UAE
13.6.2. Saudi Arabia
13.6.3. South Africa
13.6.4. Israel
13.6.5. Turkiye
13.6.6. Rest of Middle East and Africa
14. COMPETITIVE LANDSCAPE
14.1. Competitive Scenario
14.2. Market Share Analysis - Global
14.3. Market Share Analysis - North America
14.4. Market Share Analysis - Europe
14.5. Market Share Analysis - Asia-Pacific
14.6. Mergers and Acquisitions Analysis
14.7. Partner Identification Analysis
14.8. Investment & Funding Landscape
14.9. Strategic Alliances & Innovation Pipeline
15. COMPANY PROFILES
15.1. IBM*
15.1.1. Company Overview
15.1.2. Product Portfolio and Description
15.1.3. Revenue Analysis
15.1.4. Pricing Analysis
15.1.5. SWOT Analysis
15.1.6. Recent Developments
15.1.6.1. Major Deals
15.1.6.2. M&A
15.1.6.3. Collaboration
15.1.6.4. Acquisition
15.1.6.5. Joint Ventures
15.1.6.6. Innovations
15.1.7. Recent News
15.1.7.1. Events
15.1.7.2. Conferences
15.1.7.3. Symposiums
15.1.7.4. Webinars
15.2. D-Wave Quantum Inc.
15.3. Microsoft
15.4. Rigetti & Co, LLC.
15.5. Intel Corporation
15.6. Fujitsu
15.7. Xanadu
15.8. Quantum Brilliance Pty Ltd
15.9. Zapata Quantum, Inc.
15.10. QuEra Computing Inc.
15.11. Qubit Pharmaceuticals (LIST NOT EXHAUSTIVE)
16. APPENDIX
16.1. About Us and Services
16.2. Contact Us
